Jeremiah’s practice includes overall regulatory strategy, support for investigational new drug applications (INDs) or investigational device exemptions (IDEs), and support for pre-market applications, including 505(b)(1) and 505(b)(2) new drug applications (NDAs), biologics license applications (BLAs), emergency use authorizations (EUAs) for drugs and biologics, 510(k) Programs, premarket approval applications (PMAs), de novo requests for medical devices, and GxPs. He also advises clients on expedited approval mechanisms, Hatch-Waxman and Biologics Price Competition and Innovation Act of 2009 (BPCIA) regulatory frameworks, regulatory incentives (e.g., marketing exclusivity and priority review vouchers), product labeling, risk evaluation and mitigation strategies (REMS), advertising and promotion, response to FDA compliance actions (e.g., negative 483 or warning letters), and input and challenges to FDA rulemaking under the Administrative Procedures Act (APA). Jeremiah helps companies shape legislative changes to the Federal Food, Drug, and Cosmetic (FD&C) Act and the Public Health Service Act (PHSA).
His practice also includes unique expertise in agreements with the research and development (R&D) elements of the federal government. He has drafted and negotiated cooperative research and development agreements (CRADAs), Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation (DFAR) contracts, grants and cooperative agreements, other transaction agreements (OTAs), experimental supply agreements, and patent license agreements to create “win-win” collaborations between industry and the government.
As the chief of the FDA Regulatory Law Division, JAG, USAMRDC, Jeremiah advised USAMRDC and the U.S. Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Nuclear and Radiological Defense (JPEO-CBRND) on the development and regulation of medical countermeasures to treat the unique needs of U.S. soldiers. During the COVID-19 pandemic, he served as the chief coordinating counsel of the DoD JPEO-CBRND Joint Assisted Acquisition (JA2) Legal Cell, managing, staffing, and negotiating over $83 billion in COVID vaccine, therapeutic, and diagnostic capabilities for the federal government’s COVID-19 response. Prior to his DOD service, Jeremiah spent over seven years in the FDA Commissioner’s Office in the Office of the Chief Counsel (OCC) and the Office of Legislation (OL) and three years as a litigator at a large private sector law firm.